{
    "2021-08-25": [
        [
            {
                "time": "",
                "original_text": "贝达药业（300558.SZ）：盐酸恩沙替尼一线治疗适应症药品注册申请纳入优先审评审批程序",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "盐酸恩沙替尼",
                        "一线治疗",
                        "药品注册",
                        "优先审评",
                        "审批程序"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}